Eye film

 

(57) Abstract:

The invention relates to medicine, in particular to ophthalmology. Eye film contains chitosan, polyvinyl alcohol, collagenase QC and glycerin in the following ratio, wt.%: chitosan - 72, polyvinyl alcohol - 25, collagenase QC - 2, glycerol - 1. Eye film provides increased bio-stimulation of regenerative processes, reduction of terms of treatment of patients.

The invention relates to medicine, in particular to ophthalmology, and can be used in the treatment of corneal pathology: trauma, burns, trophic and degenerative disorders.

Currently widely used eye film based on collagen and other Biologicals. Collagen stimulates reparative regeneration processes due to the autoregulation of the growth of connective tissue (Schechter A. B. “the Stimulating effect of collagen and congratulated on the formation of connective tissue. Novosibirsk, 1972, T. 1, S. 51-53). The disadvantage of these drugs is allergenicity, the restriction of indications.

Known eye film consisting of the native cornea, polyacrylamide (PAA) and Rosa canina (EN 2076672, class a 61 K 37/12, go with all its positive properties of this film has several disadvantages: shredded native cornea of vodorastvorimie, that reduces the transparency of the films and reduces its transport properties; action film directed only to the stimulation of regeneration and prevention of bacterial and viral infections, it is additionally necessary to instalatii drops.

Closest to the technical essence is eye film containing crushed native cornea of the eye of cattle 0.25 g of polyvinyl alcohol 99,25 g, gammaglobulin 0.25 g, gentamicin 0.25 g (EN 2173178 a 61 L 27/24, AND 61 F 2/14, 2001).

The disadvantage of this film is that it contains a protein that can cause allergic reactions in hypersensitive films sick. In the last time there was a risk of infection of patients pionowymi infections of animals, which limits the use of biological products of animal origin.

We have been given the task to reduce the time of treatment of patients, to strengthen anti-inflammatory, antioxidant and wound healing properties of ophthalmic medical films.

To achieve the objectives of the proposed eye film based on biologically active substances containing polyvinyl alcohol, characterized in that as a therapeutic WIESHEU, wt.%:

Chitosan 72

Polyvinyl alcohol 25

Collagenase QC 2

Glycerin 1

The proposed film is rounded white with a slightly yellowish color d=15,00,03 mm Parameters of the film are determined by the micrometer in average sample. The film is fully distributed in the conjunctival cavity within 1 h

Technology of preparation of the film consists of the following steps:

1. Preparation of the solution components in 0.3 M acetic acid.

2. Casting films and drying them

In recent years, widespread byregowda therapy, including the use of biopolymers with high biological activity. Of great interest is the widespread use of natural polysaccharides, chitin and its derivative chitosan.

In the literature there are numerous reports on the application of chitosan (poly[(1-4)-2-amino-2-deoxy-D-glucose]) in medicine and biotechnology. In combination with the lack of toxicity have used a variety of properties of this polysaccharide: biocompatibility, Biodegradability and bioactivity, including the ability to plenkoobrazovatel.

With another with whom limnologie, which also promotes resorption of scars. Therefore, to obtain films we used chitosan as a binder component, degradation products which possess wound healing properties, and as destructible agent - collagenase QC. Although collagenase QC is not a traditional enzyme used for degradation of chitosan, in the literature there is evidence that the enzymatic hydrolysis of chitosan by 1-4 glycosidic--communication can be carried out under the action of non-specific enzymes, such as papain.

The data obtained show that in the presence of collagenase QC, taken in an amount of 1-2% compared to chitosan, in suspension at temperatures of 25-35C is falling values as relative, and the characteristic viscosity over time, indicating a decrease in molecular weight of the polymer, i.e. its destruction. Finding - enzymatic degradation of chitosan under the action of collagenase QC may be of interest to more low molecular weight chitosan preparations.

The method of preparation of the film:

In a sterile flask with a capacity of 200 ml fill in 100 ml of a 0.3 M solution of acetic acid and bring the temperature up to 60C, dot the resulting solution to room temperature and contribute 1.44 g of chitosan. The contents again stirred on a magnetic stirrer until dissolved. Add 0.02 g of glycerol and 0.04 g of collagenase QC. The solution is stirred for 5 minutes then pour the contents into a sterile form for the preparation of films and dried at room temperature. After drying the resulting film is removed from the form and placed in a plastic bag, sealed package.

Method of application: eye film on the surface of the cornea (like contact lenses) 2-3 times a day.

Eye film prepared from the following components, wt%:

The ratio of components, wt.%:

Chitosan 72

Polyvinyl alcohol 25

Collagenase QC 2

Glycerin 1

meets the requirements of Pharmacopoeia XI

Example 1

On the model of measured defect of the cornea of the rabbit was studied therapeutic effectiveness of the proposed eye films. Eye film was laid in the right eye 3 times a day. The left eye served as a control: buried 30% solution sulfatsila sodium 3 times a day.

Histological, electron microscopic studies show that complete epithelialization of the defect of the cornea begins at 7 with the displacement of the cornea with the proper orientation of the collagen fibers and early differentiation of cellular elements.

Eye film easy to use, have a prolonged adhesive properties. Reduce the time of treatment of patients, on average, 3-4 days, improve functional outcomes.

Eye film based on biologically active substances containing polyvinyl alcohol, characterized in that as a biologically active substance using chitosan and further comprises collagenase QC, polyvinyl alcohol and glycerin in the following ratio, wt.%:

Chitosan 72

Polyvinyl alcohol 25

Collagenase QC 2

Glycerin 1

 

Same patents:
The invention relates to agriculture, in particular animal health, and can be used to treat horses, patients relapsing iridocyclitis
The invention relates to agriculture, in particular animal health, and can be used to treat horses, patients relapsing iridocyclitis

The invention relates to the field of medicine and relates to a composition for topical application, reducing intraocular pressure, comprising the antagonist of angiotensin II, boric acid and ethylenediaminetetraacetic acid
The invention relates to medicine, in particular to ophthalmology, and can be used in the treatment pseudophoenix diseases of the orbit

The invention relates to medicine, in particular to ophthalmology, and can be used as ophthalmic medicines for the treatment of diseases and injuries of the cornea
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of patients with diabetic retinopathy
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of postinflammatory bullous keratopathy

The invention relates to medicine, namely to ophthalmology, and for the treatment of edematous maculopathy
The invention relates to medicine, namely to ophthalmology, and for the prevention of postoperative complications antiglaucomatous surgery
The invention relates to medicine, namely to ophthalmology, and for the treatment of endocrine ophthalmopathy
The invention relates to medicine, namely to the technology of production of medical preparations from human blood plasma

the enzyme" target="_blank">

The invention relates to the field of medicine and biotechnology and relates to DNA sequences encoding human proteins TX and The related converging interleukin-1-beta enzyme

The invention relates to medicine, in particular to the pharmaceutical industry
The invention relates to medicine, namely to a gastroenterologist, and for the treatment of acute pancreatitis

The invention relates to native proteins schemes complement modified such that the protein is able to form stable C3 to Mac

The invention relates to medicine
The invention relates to medicine, namely to a gastroenterologist, and for the prevention of acute pancreatitis
The invention relates to medicine, more precisely to skin diseases, and can be used for the treatment of prurigo, urticaria and red flat lichen
The invention relates to medicine, namely to surgery, and can be used for the treatment of purulent wounds
The invention relates to medicine

The invention relates to medicine, can be used in surgery
Up!